Colchicine will lower C-reactive protein (CRP) in chronic atrial fibrillation and reduce the rise in CRP which occurs following atrial fibrillation ablation
Three groups of patients will be randomized to colchicine 0.6 mg PO bis in die (BID) or matching placebo: 1. Paroxysmal atrial fibrillation, pre-ablation 2. Persistent atrial fibrillation, pre-ablation 3. Chronic persistent atrial fibrillation
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
26
Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
Mayo Clinic Florida
Jacksonville, Florida, United States
Change in C-reactive Protein
Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.
Time frame: baseline, day 28
Number of Subjects With Atrial Fibrillation
All subjects will have 12 lead ECG on day 28 to measure the number of subjects with normal sinus rhythm and atrial fibrillation.
Time frame: day 28
Time Course of C-reactive Protein Levels
Plasma levels of C-reactive protein was determined by the immunoprecipitation method using an in vitro diagnostic assay.
Time frame: baseline, day 3, day 7, day 14, day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.